Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Drinabant (AVE-1625) is an orally active CB1 receptor antagonist. Drinabant inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 132.00 | |
2 mg | In stock | $ 197.00 | |
5 mg | In stock | $ 297.00 | |
10 mg | In stock | $ 455.00 | |
25 mg | In stock | $ 748.00 | |
50 mg | In stock | $ 1,050.00 | |
100 mg | In stock | $ 1,420.00 | |
500 mg | In stock | $ 2,850.00 |
Description | Drinabant (AVE-1625) is an orally active CB1 receptor antagonist. Drinabant inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R. |
In vivo | Drinabant (10 mg/kg orally once daily), combined with Olanzapine attenuates body weight gain, diminishing the enhanced food intake while maintaining increased energy expenditure and decreased motility[2]. Drinabant (1, 3, and 10 mg/kg ip), reverses abnormally persistent LI induced by MK-801 or neonatal nitric oxide synthase inhibition in rodents, and improves both working and episodic memory[3]. |
Synonyms | AVE-1625, AVE1625 |
Molecular Weight | 497.38 |
Formula | C23H20Cl2F2N2O2S |
CAS No. | 358970-97-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/ml (20.1 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Drinabant 358970-97-5 GPCR/G Protein Cannabinoid Receptor AVE-1625 AVE1625 AVE 1625 inhibitor inhibit